TY - JOUR
T1 - PJ3-047 Site Specific Effects of Quinidine on Repolarization Abnormalities in Patiens with Brugada Type ECG by Using Body Surface Mapping System
AU - Taniyama, Makiko
AU - Morita, Hiroshi
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2011
Y1 - 2011
N2 - Brugada syndrome (BS) is characterized by ST-elevation in leads V1-3, and coexistence of the early repolarization in the left-lateral or inferior leads has been reported as a predictor of VF episodes. Quinidine is a candidate of terapeutic drugs and decreases ST level in some patients. We evaluate the effects of quinidine on ST elevation in three ventricular sites (RVOT, Inferior part and LV) by using body surface mapping system (BSM).We enroled 36 patients with BS-type ECG (asymptomatic 22 pts, VF 11 pts). We recorded ECGs and BSM before and after administration of quinidine (200mg,p. o.) and measured the ECG parameters and the voltage of the ST segment 20ms after J point (ST 20) by the BSM. There were no differences in RR,PQ, and QRS intervals before and after quinidine administration. ST elevation (V2) was attenuated after quinidine treatment (before: 0.28± 0.14mV,v. s. after: 0.23 ± 0.13mV, p=0.03). BSM: ST20 was the highest in the RVOT before quinidine treatment. Quinidine attenuated the ST elevation in the RVOT in VF group (before: 0.23±0.16 mV, v.s. after: 0.16±0.12 mV, p<0.01) and asymptomatic group (before: 0.20±0.13 mV,v.s. after: 0.18± 0.12 mV, p<0.01) but not in other areas. Quinidine improved repolarization abnormality in the RVOT specifically, but not in other areas. The mechanism of the ST elevation in LV and INF might be different from the RVOT.
AB - Brugada syndrome (BS) is characterized by ST-elevation in leads V1-3, and coexistence of the early repolarization in the left-lateral or inferior leads has been reported as a predictor of VF episodes. Quinidine is a candidate of terapeutic drugs and decreases ST level in some patients. We evaluate the effects of quinidine on ST elevation in three ventricular sites (RVOT, Inferior part and LV) by using body surface mapping system (BSM).We enroled 36 patients with BS-type ECG (asymptomatic 22 pts, VF 11 pts). We recorded ECGs and BSM before and after administration of quinidine (200mg,p. o.) and measured the ECG parameters and the voltage of the ST segment 20ms after J point (ST 20) by the BSM. There were no differences in RR,PQ, and QRS intervals before and after quinidine administration. ST elevation (V2) was attenuated after quinidine treatment (before: 0.28± 0.14mV,v. s. after: 0.23 ± 0.13mV, p=0.03). BSM: ST20 was the highest in the RVOT before quinidine treatment. Quinidine attenuated the ST elevation in the RVOT in VF group (before: 0.23±0.16 mV, v.s. after: 0.16±0.12 mV, p<0.01) and asymptomatic group (before: 0.20±0.13 mV,v.s. after: 0.18± 0.12 mV, p<0.01) but not in other areas. Quinidine improved repolarization abnormality in the RVOT specifically, but not in other areas. The mechanism of the ST elevation in LV and INF might be different from the RVOT.
KW - Brugada syndrome
KW - body surface mapping
KW - quinidine administration
UR - http://www.scopus.com/inward/record.url?scp=85008722288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85008722288&partnerID=8YFLogxK
U2 - 10.4020/jhrs.27.PJ3_047
DO - 10.4020/jhrs.27.PJ3_047
M3 - Article
AN - SCOPUS:85008722288
SN - 1880-4276
VL - 27
JO - journal of arrhythmia
JF - journal of arrhythmia
ER -